Sanford C. Bernstein Lowers Abbott Laboratories (NYSE:ABT) Price Target to $125.00

Abbott Laboratories (NYSE:ABT) had its price objective reduced by equities research analysts at Sanford C. Bernstein from $154.00 to $125.00 in a report released on Friday,Benzinga reports. The firm presently has an “outperform” rating on the healthcare product maker’s stock. Sanford C. Bernstein’s price target would suggest a potential upside of 14.95% from the stock’s previous close.

A number of other brokerages also recently commented on ABT. Oppenheimer reduced their price objective on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research report on Friday. The Goldman Sachs Group reduced their target price on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research report on Friday. Royal Bank Of Canada decreased their price target on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research note on Friday. Benchmark began coverage on shares of Abbott Laboratories in a research note on Friday, October 10th. They issued a “buy” rating and a $145.00 price objective for the company. Finally, Evercore ISI decreased their target price on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $141.84.

Abbott Laboratories Stock Up 0.1%

ABT traded up $0.14 during midday trading on Friday, hitting $108.75. 5,161,265 shares of the company’s stock traded hands, compared to its average volume of 9,150,906. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. The company has a market cap of $189.10 billion, a PE ratio of 13.64, a price-to-earnings-growth ratio of 2.00 and a beta of 0.72. Abbott Laboratories has a one year low of $105.78 and a one year high of $141.23. The stock’s fifty day simple moving average is $125.23 and its 200-day simple moving average is $128.54.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.60%. The business had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter last year, the firm earned $1.34 EPS. Abbott Laboratories’s revenue for the quarter was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Institutional Trading of Abbott Laboratories

Several large investors have recently made changes to their positions in the business. TCV Trust & Wealth Management Inc. increased its position in Abbott Laboratories by 3.9% in the 4th quarter. TCV Trust & Wealth Management Inc. now owns 123,773 shares of the healthcare product maker’s stock valued at $15,508,000 after acquiring an additional 4,649 shares in the last quarter. Fortune Financial Advisors LLC increased its holdings in shares of Abbott Laboratories by 2.5% in the fourth quarter. Fortune Financial Advisors LLC now owns 12,406 shares of the healthcare product maker’s stock valued at $1,554,000 after purchasing an additional 302 shares in the last quarter. Brown Lisle Cummings Inc. raised its position in Abbott Laboratories by 14.6% in the 4th quarter. Brown Lisle Cummings Inc. now owns 4,706 shares of the healthcare product maker’s stock worth $590,000 after purchasing an additional 600 shares during the last quarter. Capital Planning LLC lifted its holdings in Abbott Laboratories by 135.1% during the 4th quarter. Capital Planning LLC now owns 18,758 shares of the healthcare product maker’s stock worth $2,330,000 after buying an additional 10,780 shares in the last quarter. Finally, Aljian Capital Management LLC boosted its position in Abbott Laboratories by 4.7% in the 4th quarter. Aljian Capital Management LLC now owns 5,127 shares of the healthcare product maker’s stock valued at $642,000 after buying an additional 230 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Several sell‑side analysts kept constructive ratings and still see meaningful upside — Piper Sandler cut its price target to $135 but remains “overweight,” and BTIG trimmed its target to $140 while keeping a “buy” call, signaling continued analyst confidence despite the pullback. Benzinga
• Positive Sentiment: Med tech (devices) and Established Pharmaceuticals delivered strong growth (double‑digit devices, mid‑single to high single pharma), which management says helped offset weakness in other segments and supports the company’s multi‑year growth thesis. Blockonomi
• Positive Sentiment: Market commentators view the pullback as a potential buying opportunity for long‑term investors because Abbott remains a cash‑generative Dividend King with capacity for buybacks and continued margin improvement. MarketBeat
• Neutral Sentiment: Adjusted EPS of $1.50 matched consensus, showing underlying earnings resilience even as revenues lagged; GAAP results included items that lowered headline net income. Press Release
• Neutral Sentiment: Company guidance: Q1 2026 adjusted EPS of $1.120–1.180 (below the ~1.20 consensus) and FY 2026 adjusted EPS of $5.55–5.80 (around consensus). Guidance tempered near‑term expectations but keeps mid/longer‑term growth intact. Press Release
• Negative Sentiment: Revenue missed Street estimates (~$11.46–11.5B reported vs. ~$11.8–11.9B expected); the Nutrition business declined sharply (near‑9% year‑over‑year) and Diagnostics weakened (lower COVID testing and volatility), which triggered the market sell‑off. Reuters Blockonomi
• Negative Sentiment: Unusual bearish positioning: intraday put option volume spiked sharply, indicating heavy hedging or speculative bearish bets that can amplify downward price moves. (Reported market activity)
• Negative Sentiment: Regulatory/legal overhang: documents show India regulators are scrutinizing supply of a codeine‑based cough syrup tied to abuse investigations, introducing potential reputational and compliance risk. Reuters

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.